## Contractor Information

<table>
<thead>
<tr>
<th>CONTRACTOR NAME</th>
<th>CONTRACT TYPE</th>
<th>CONTRACT NUMBER</th>
<th>JURISDICTION</th>
<th>STATES</th>
</tr>
</thead>
<tbody>
<tr>
<td>National Government Services, Inc.</td>
<td>MAC - Part A</td>
<td>06101 - MAC A</td>
<td>J - 06</td>
<td>Illinois</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>MAC - Part B</td>
<td>06102 - MAC B</td>
<td>J - 06</td>
<td>Illinois</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>MAC - Part A</td>
<td>06201 - MAC A</td>
<td>J - 06</td>
<td>Minnesota</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>MAC - Part B</td>
<td>06202 - MAC B</td>
<td>J - 06</td>
<td>Minnesota</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>MAC - Part A</td>
<td>06301 - MAC A</td>
<td>J - 06</td>
<td>Wisconsin</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>MAC - Part B</td>
<td>06302 - MAC B</td>
<td>J - 06</td>
<td>Wisconsin</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>A and B and HHH MAC</td>
<td>13101 - MAC A</td>
<td>J - K</td>
<td>Connecticut</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>A and B and HHH MAC</td>
<td>13102 - MAC B</td>
<td>J - K</td>
<td>Connecticut</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>A and B and HHH MAC</td>
<td>13202 - MAC B</td>
<td>J - K</td>
<td>New York - Downstate</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>A and B and HHH MAC</td>
<td>13282 - MAC B</td>
<td>J - K</td>
<td>New York - Upstate</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>A and B and HHH MAC</td>
<td>14111 - MAC A</td>
<td>J - K</td>
<td>Maine</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>A and B and HHH MAC</td>
<td>14112 - MAC B</td>
<td>J - K</td>
<td>Maine</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>A and B and HHH MAC</td>
<td>14211 - MAC A</td>
<td>J - K</td>
<td>Massachusetts</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>A and B and HHH MAC</td>
<td>14212 - MAC B</td>
<td>J - K</td>
<td>Massachusetts</td>
</tr>
<tr>
<td>CONTRACTOR NAME</td>
<td>CONTRACT TYPE</td>
<td>CONTRACT NUMBER</td>
<td>JURISDICTION</td>
<td>STATES</td>
</tr>
<tr>
<td>----------------------</td>
<td>-----------------------------------</td>
<td>------------------</td>
<td>--------------</td>
<td>-----------------</td>
</tr>
<tr>
<td>Inc. Inc.</td>
<td>MAC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>A and B and HHH MAC</td>
<td>14311 - MAC A</td>
<td>J - K</td>
<td>New Hampshire</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>A and B and HHH MAC</td>
<td>14312 - MAC B</td>
<td>J - K</td>
<td>New Hampshire</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>A and B and HHH MAC</td>
<td>14411 - MAC A</td>
<td>J - K</td>
<td>Rhode Island</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>A and B and HHH MAC</td>
<td>14412 - MAC B</td>
<td>J - K</td>
<td>Rhode Island</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>A and B and HHH MAC</td>
<td>14511 - MAC A</td>
<td>J - K</td>
<td>Vermont</td>
</tr>
<tr>
<td>National Government Services, Inc.</td>
<td>A and B and HHH MAC</td>
<td>14512 - MAC B</td>
<td>J - K</td>
<td>Vermont</td>
</tr>
</tbody>
</table>

**LCD Information**

**Document Information**

**LCD ID**
L39226

**LCD Title**
Multiplex Gastrointestinal Pathogen Panel (GPP) Tests for Acute Gastroenteritis (AGE)

**Proposed LCD in Comment Period**
N/A

**Source Proposed LCD**
DL39226

**Original Effective Date**
For services performed on or after 08/01/2022

**Revision Effective Date**
N/A

**Revision Ending Date**
N/A

**Retirement Date**

AMA CPT / ADA CDT / AHA NUBC Copyright Statement

CPT codes, descriptions and other data only are copyright 2022 American Medical Association. All Rights Reserved. Applicable FARS/HHSARS apply.

Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

Current Dental Terminology © 2022 American Dental Association. All rights reserved.

Copyright © 2023, the American Hospital Association, Chicago, Illinois. Reproduced with permission. No portion of the American Hospital Association (AHA) copyrighted materials contained within this publication may be copied without the express written consent of the AHA. AHA copyrighted materials including the UB04 codes and descriptions may not be removed, copied, or utilized within any software, product, service, solution or derivative work without the written consent of the AHA. If an entity wishes to utilize any AHA materials, please contact the AHA at 312-893-6816.

Making copies or utilizing the content of the UB04 Manual, including the codes and/or descriptions, for internal purposes, resale and/or to be used in any product or publication; creating any modified or derivative work of the UB04 Manual and/or codes and descriptions; and/or making any commercial use of UB04 Manual or any portion thereof, including the codes and/or descriptions, is only authorized with an express license from
Notice Period Start Date
06/16/2022

Notice Period End Date
07/31/2022

Issue

Issue Description

The CDC estimates nearly 48 million AGE US cases annually, costing approximately $150M (3). A wide spectrum of responsible enteric pathogens include bacteria (e.g., campylobacter, clostridium difficile, salmonella, shigella, vibrio, yersinia); viruses (e.g., norovirus, rotavirus, astrovirus, adenovirus); and parasites (e.g., giardia, entamoeba histolytica and cryptosporidium). AGE cases are usually self-limited with no laboratory testing recommended except for certain populations such as immunocompromised hosts, the critically ill, and those with prolonged disease refractory to treatment. Therefore, in select cases, expeditious pathogen identification is important to facilitate appropriate therapy, local infection control, and epidemiologic measures.

Limited coverage is provided for Multiplex Gastrointestinal Pathogen Panel (GPP) Tests for Acute Gastroenteritis (AGE), based upon the Indications and Limitations of Coverage criteria.

CMS National Coverage Policy

Language quoted from Centers for Medicare and Medicaid Services (CMS), National Coverage Determinations (NCDs) and coverage provisions in interpretive manuals is italicized throughout the policy. NCDs and coverage provisions in interpretive manuals are not subject to the Local Coverage Determination (LCD) Review Process (42 CFR 405.860[b] and 42 CFR 426 [Subpart D]). In addition, an administrative law judge may not review an NCD. See Section 1869(f)(1)(A)(i) of the Social Security Act.

Unless otherwise specified, italicized text represents quotation from one or more of the following CMS sources:

**Title XVIII of the Social Security Act (SSA):**
Section 1862(a)(1)(A) excludes expenses incurred for items or services which are not reasonable and necessary for the diagnosis or treatment of illness or injury or to improve the functioning of a malformed body member.
Section 1833(e) prohibits Medicare payment for any claim which lacks the necessary information to process the claim.
Section 1862(a)(7) excludes routine physical examinations, unless otherwise covered by statute.

**CMS Publications:**
CMS Publication 100-02, *Medicare Benefit Policy Manual*, Chapter 15, Section 80.1 – Laboratory services must meet applicable requirements of CLIA

CMS Publication 100-04, *Medicare Claims Processing Manual*, Chapter 16, Section 40.7 Billing for Noncovered Clinical Laboratory Tests Section and 120.1 Clarification of the Use of the Term “Screening” or “Screen”
Code of Federal Regulations:

42 CFR, Section 410.32, indicates that diagnostic tests may only be ordered by the treating physician (or other treating practitioner acting within the scope of his or her license and Medicare requirements) who furnishes a consultation or treats a beneficiary for a specific medical problem and who uses the results in the management of the beneficiary's specific medical problem. Tests not ordered by the physician (or other qualified non-physician provider) who is treating the beneficiary are not reasonable and necessary (see Sec. 411.15(k)(1) of this chapter).

Coverage Guidance

Coverage Indications, Limitations, and/or Medical Necessity

Indications and Limitations of Coverage*

One† multiplex GPP^ is covered when at least ONE of the following applies:

1. Community-acquired acute diarrhea (≥3 loose or watery stools/day for ≤14 days) with at least ONE of the following (1-3):
   a. >1 week duration
   b. Severe illness (e.g., profuse watery diarrhea, signs of hypovolemia, passage of ≥6 unformed stools per 24 hours, severe abdominal pain, need for hospitalization)
   c. Inflammatory diarrhea (bloody diarrhea, small volume mucous stools, fever)
   d. High-risk host (e.g., age ≥70 years, cardiac disease, immunocompromising condition, inflammatory bowel disease, pregnancy)
   e. Public health concerns (e.g., food handler, health care or day care worker)
2. Pre-transplant evaluation (4)

Contraindications to Coverage (ANY)

1. As a test of cure (3,5)
2. More than 72 hr. after hospitalization while still an inpatient (1,6-8)
3. Laxatives in the prior 48 hours (7, 32), excluding those with signs of severe disease
*See associated Billing & Coding article for specific diagnosis codes, POS, and credentialing requirements.

†A second panel test for the same clinical indication is covered if the first panel yielded a negative result AND there is a high index of suspicion for a pathogen as the cause of symptoms, AND the patient’s clinical condition is not improving or is deteriorating, AND as long as the test fulfills the criteria for coverage set forth in the LCD.

Tests must be FDA approved/cleared, or if a laboratory developed test (LDT), have a published, peer-reviewed study supporting analytic validity, or certification by a third-party consistent with the New York State Department of Health’s Clinical Laboratory Evaluation Program (CLEP) review standards.

Summary of Evidence

The CDC estimates nearly 48 million AGE US cases annually, costing approximately $150M (3). A wide spectrum of responsible enteric pathogens include bacteria (e.g., campylobacter, clostridium difficile, salmonella, shigella, vibrio, yersinia); viruses (e.g., norovirus, rotavirus, astrovirus, adenovirus); and parasites (e.g., giardia, entamoeba histolytica and cryptosporidium) (3,9). AGE cases are usually self-limited with no laboratory testing recommended (10) except for certain populations such as immunocompromised hosts, the critically ill, and those with prolonged disease refractory to treatment. Sequelae can include Guillain-Barré syndrome, reactive arthritis, irritable bowel syndrome, malabsorption syndrome, or hemolytic uremic syndrome (11). Therefore, in select cases, expeditious pathogen identification is important to facilitate appropriate therapy, local infection control, and epidemiologic measures.

Traditionally, diarrheal pathogens have been identified using cultures for bacteria, monoplex (one-target) polymerase chain reaction (PCR) assays for viruses, and microscopy or enzyme immunoassays (EIA) for parasites. However, such methods are time-consuming, labor-intensive, operator-dependent, and often involve test selection based on clinically indistinguishable illness (12). Turn-around times of several days is typical, during which a patient is isolated with empiric or no therapy (13). Recently, multiplex GPPs, which exploit multiplex nucleic acid amplification methodology, have gained traction due to reduced sample volume requirements, broad coverage without the need to select specific tests, enhanced ability to detect coinfections, increased sensitivity, higher throughput, and faster turnaround time to ≤ 1 day (9,12).

Three longstanding FDA-approved/cleared multiplex GPP assays that detect >5 stool pathogens are the Luminex xTAG gastrointestinal pathogen panel (Luminex GPP; Luminex Corporation, FDA approval/clearance 2013, 14 targets), the BioFire FilmArray gastrointestinal panel (BioFire GIP; BioFire Diagnostics, FDA approval/clearance 2014, 22 targets), and the Verigene Enteric Pathogens panel (Verigene EP, Luminex Corporation, FDA approval/clearance 2014, 9 targets) (14). A substantial body of research evaluating the BioFire GIP and Luminex GPP is available and demonstrates that both assays yield more positive results (22-74%) than conventional testing (8-18%) methods (15-17), likely due to a combination of greater sensitivity and target number. The most commonly detected organisms are C. difficile, enteropathogenic E. coli (EPEC), enteroaggregative E. coli (EAEC), salmonella, norovirus, rotavirus, sapovirus, and cryptosporidium (15-19). One study comparing GPPs to conventional testing in 152 stool samples with AGE found the range of sensitivity/specificity to different pathogens common to each was BioFire (94.7-100%/98.6-100%), Luminex (79.2-100%/100%), Verigene (71.4-95.4%/99.1-100%) (20). All three GPPs detected the majority of gastrointestinal pathogens when compared to conventional methods.

Multiplex GPPs consistently detect multiple targets more frequently than conventional testing. One study of 709 samples found multiple pathogens in 16.4% of samples using the BioFire GIP versus 1% after conventional testing (17). Among samples with multiple pathogens, 84% were positive for EAEC or EPEC. Impact studies have found that
GPP testing is associated with a significant decrease in endoscopic procedures, abdominal imaging, antibiotic use, and reduced hospital length of stay (7,11,21). A prospective multi-center study evaluating 1887 fecal specimens from patients with AGE found that use of a GI panel enhanced organism detection and improved clinical sensitivity, and enabled clinicians to provide more timely and targeted antimicrobial therapy (22). Positive Shiga-like toxin producing E. coli (STEC) results led to appropriate discontinuation of empiric antibiotics sooner. A study in patients with inflammatory bowel disease (IBD) found that GPP testing led to lower rate of IBD treatment modification (23). In outpatients with IBD relapse, testing was associated with significantly lower rates of IBD therapy escalation and endoscopy compared to patients who underwent conventional testing (24). A study evaluating GI infections prior to hematopoietic cell transplantation (HCT) in 112 asymptomatic patients found more than one-third were colonized with a wide range of GI pathogens, with colonization predicting the infectious etiology of post-transplantation diarrhea in nearly 75% of cases (4). The authors suggest that pre-transplant GPP testing may be warranted in asymptomatic patients.

A systematic review and meta-analysis of 10 studies compared GPP tests with standard microbiology techniques in patients with suspected AGE (25). The authors determined that no study provided an adequate reference standard with which to compare the test accuracy of GPP and conventional tests. In the absence of a reference standard, test performance was analyzed taking GPP tests and standard microbiology techniques in turn as the benchmark test, using random effects meta-analysis of proportions. Positive agreement across all pathogens was 0.93 (95% CI 0.90 to 0.96) when conventional methods were the benchmark and 0.68 (95% CI: 0.58 to 0.77) when GPP provided the benchmark. Negative agreement was high in both instances due to the high proportion of negative cases. The authors conclude: “GPP testing has the potential to simplify testing and accelerate reporting when compared to conventional microbiology methods. However the impact of GPP testing upon the management, treatment and outcome of patients is poorly understood and further studies are needed to evaluate the health economic impact of GPP testing compared with standard methods...GPP testing produced a greater number of pathogen-positive findings than conventional testing. It is unclear whether these additional 'positives' are clinically important.”

Another systematic review and meta-analysis included 11 studies with 7085 stool samples (12). Multiplex PCRs demonstrated high diagnostic accuracy, with specificity ≥0.98 and area under the ROC curve (AUROC) ≥0.97 for all the pathogens except for Yersinia enterocolitica (AUROC 0.91). The Biofire GIP demonstrated a higher sensitivity than Luminex xTAG GPP for most of the pathogens with the exception of Rotavirus A (xTAG GPP and Biofire GIP were both 0.93). They conclude that “both GI panels are highly accurate and may provide important diagnostic information for early identification of gastroenteritis.”

While apparent superiority of fundamentals such as sensitivity and specificity are important, findings can be challenging to interpret when there is no clear “gold standard”. “Pathogens detected may represent colonization, asymptomatic infection, reactivation in the setting of acute infection, chromosomal integration, or prolonged shedding after an unrelated prior infection” (26). Detection of nucleic acids does not necessarily equate to detection of a viable organism responsible for the patient’s disease. Interpretation complexity is exacerbated by inappropriate use; a retrospective, observational, cohort study of 442 BioFire GIP tests found that 61% were deemed inappropriately ordered (7). Primary reasons were lack of documented diarrhea (n = 92), greater than 2 days of hospitalization (n = 116), having a duplicate C. difficile PCR test ordered (n = 118), or laxative use in the 48 hours before testing (n = 36). Another study of 481 BioFire GIP tests found a low diagnostic yield (3%) in adult patients hospitalized for >72 hours (6). Careful diagnostic and antimicrobial stewardship is essential for responsible GPP implementation (6-8,14,26).

Analysis of Evidence (Rationale for Determination)

Studies show multiplex GPP testing produces a greater number of pathogen-positive findings than conventional
testing, with overall high sensitivity and specificity. This led to a paradigm shift in AGE diagnosis, providing a single test to detect a number of organisms associated with an infectious syndrome rather than a series of individual, pathogen-specific assays (14). Reducing turnaround time from days to hours facilitates earlier, specific (non-empiric) antibiotic treatment.

Guidelines from the American College of Gastroenterology (ACG) regarding acute diarrheal infections in adults are supportive of multiplex GPPs as a potential alternative to traditional tests (3).

1. Stool diagnostic studies may be used if available in cases of dysentery, moderate-to-severe disease, and symptoms lasting >7 days to clarify the etiology of the patient’s illness and enable specific directed therapy. (Strong recommendation, very low level of evidence).
2. Historical guidelines for diagnostic testing (ACG, IDSA) seem to be too restrictive in the current environment of new diagnostic methods and enhanced ability to target therapy.
3. Traditional methods of diagnosis (bacterial culture, microscopy with and without special stains and immunofluorescence, and antigen testing) fail to reveal the etiology of the majority of cases of acute diarrheal infection. If available, the use of FDA-approved culture independent methods of diagnosis can be recommended at least as an adjunct to traditional methods. (Strong recommendation, low level of evidence).
4. Several well-designed studies show that molecular testing now surpasses all other approaches for the routine diagnosis of diarrhea. Molecular diagnostic tests can provide a more comprehensive assessment of disease etiology by increasing the diagnostic yield compared with conventional diagnostic tests. They are also faster, providing results in hours rather than days.
5. One potential drawback of molecular technologies is the need to predefine the particular microbes being sought. In addition the significance of an identified organism may not be clear as these molecular technologies, which involve nucleic acid amplification, are limited to our existing knowledge of a microbes’ genome and do not discriminate between viable and non-viable organisms.

Guidelines from the Infectious Diseases Society of America (ISDA) are also generally supportive of multiplex GPPs with some caveats (5).

1. Stool culture often fails to detect the causative agent and, when necessary, culture-independent methods are recommended as adjunct methods.
2. Selective use of multiplex nucleic acid amplification tests (NAATs) for stool pathogens is very sensitive and, when positive for reportable agents, should either be cultured to recover the isolate or the stool provided to public health laboratories to culture, for epidemiologic follow-up.
3. Culture independent methods can detect pathogens in as little as 1–5 hours compared to the 24–96 hours often required for culture. These assays are reported to be more sensitive than culture and have resulted in much higher rates of detection.
4. Highly multiplexed assays allow for the detection of mixed infections, where the importance of each pathogen is unclear, and they may allow for the detection of pathogens, such as enteroaggregative E. coli or sapovirus, where the indication for therapy is unclear.
5. Culture-independent methods should not be used as test of cure as they will detect both viable and non-viable organisms.

Other analyses remain guarded. A 2017 National Institute for Health and Care Excellence (NICE) guideline (27), based on a Health Technology Assessment (28), is circumspect: “There is currently insufficient evidence to recommend the routine adoption in the NHS of the integrated multiplex PCR tests, xTAG Gastrointestinal Pathogen Panel, FilmArray GI Panel and Faecal Pathogens B assay, for identifying gastrointestinal pathogens in people with suspected gastroenteritis.” No study reported on change in management by test outcome, health-related quality of life, morbidity or mortality. They acknowledge the tests show promise but recommend further research on their effect on health outcomes and resource use. UpToDate somewhat tepidly recommends multiplex molecular testing “if
culture is not available” (1). They suggest that any GPP positive for a bacterial pathogen be submitted for confirmatory culture and echo the call for caution relative to co-detections: “a high degree of clinical correlation is necessary when interpreting results of molecular testing since these assays detect genetic material, which does not always indicate infection with a viable organism, and identification of more than one pathogen is not uncommon.” Some commercial coverage of some highly multiplexed GPPs (> 5 targets) is either very restrictive (29), or absent (30,31).

In summary, studies and guidelines mostly agree that 1/ any diagnostic testing for AGE should be very selective since most cases are self-limited; 2/ multiplex GPPs can serve as an adjunct or alternative to conventional testing; and 3/ the increased sensitivity of highly multiplexed GPPs can be a double-edged sword, with targets of questionable clinical significance (even potentially nonviable), complicating interpretation. These new challenges, along with the potential for inappropriate testing, emphasize the need for enhanced diagnostic acumen, especially for more highly multiplexed GPPs. The greater the target number, the greater the interpretive complexity; the greater the interpretive complexity, the greater the need for clinician expertise and diagnostic stewardship.

General Information

Associated Information

N/A

Sources of Information

N/A

Bibliography

10. Shane AL, Mody RK, Crump JA, et al. 2017 Infectious Diseases Society of America Clinical Practice
27. NICE Guideline: The detection of nucleic acids by molecular diagnostics does not always equate to detection of a viable organism that is the cause of the patient’s disease process. Pathogens detected may represent colonization, asymptomatic infection, reactivation in the setting of acute infection, chromosomal integration, or prolonged shedding after an unrelated prior infection. 2017; NICE Guideline. Accessed 11/20/21.


---

**Revision History Information**

N/A

**Associated Documents**

**Attachments**
N/A

**Related Local Coverage Documents**

**Articles**

- A59088 - Response to Comments: Multiplex Gastrointestinal Pathogen Panel (GPP) Tests for Acute Gastroenteritis (AGE)

**Related National Coverage Documents**
N/A

**Public Versions**

<table>
<thead>
<tr>
<th>UPDATED ON</th>
<th>EFFECTIVE DATES</th>
<th>STATUS</th>
</tr>
</thead>
<tbody>
<tr>
<td>06/06/2022</td>
<td>08/01/2022 - N/A</td>
<td>Currently in Effect (This Version)</td>
</tr>
</tbody>
</table>

**Keywords**

N/A